Surgery—with or without postoperative radioiodine—is the standard of care for most patients
with differentiated thyroid carcinoma (DTC). Thyroid hormone replacement therapy is the …

Low-risk papillary cancers, which represent the vast majority of thyroid cancers diagnosed
today, do not require aggressive treatment or follow-up. Initial treatment consists of a total …

Background: The optimal serum thyrotropin (TSH) level for postlobectomy papillary thyroid
carcinoma (PTC) patients is unclear. The objective of this study was to examine the …

Background Thyroid lobectomy is recommended as the primary treatment for low-risk thyroid
cancer. However, recurrence and hypothyroidism may develop after lobectomy …

Objective Thyroid‐stimulating hormone (TSH) suppression treatment can induce signs and
symptoms of hyperthyroidism and hypothyroidism due to inappropriate treatment or poor …

Background Postoperative thyroid stimulating hormone (TSH) suppression therapy is
recommended for patients with intermediate-and high-risk differentiated thyroid cancer to …

Objective Since papillary thyroid cancer (PTC) patients with pre-ablation stimulated
thyroglobulin (s-Tg)< 1 ng/mL generally have a favorable prognosis, is TSH suppression still …

Simple Summary In order to reduce the recurrence rate after surgical treatment of
differentiated thyroid cancer (DTC), suppression of thyroid-stimulating hormone (TSH) or …

Context Current guidelines recommend a selective use of radioiodine treatment (RAI) for
papillary thyroid cancer (PTC). Objective This work aimed to determine how policy changes …

Introduction To evaluate the adequacy of TSH suppression therapy (TSHst) at the first
disease assessment and the last follow-up visit. Methods Retrospective observational study …